Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Myriad Genetics	Heska	Riot Blockchain	Lantheus	Celldex Therapeutics
Symbol	NASDAQ:MYGN	NASDAQ:HSKA	NASDAQ:RIOT	NASDAQ:LNTH	NASDAQ:CLDX
Price Information
Current Price	$28.80	$180.48	$48.40	$21.33	$23.71
52 Week Range	Hold	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.0	1.4	1.3	1.7	1.8
Analysis Score	0.9	2.5	3.5	2.4	3.5
Community Score	1.9	2.4	2.6	2.5	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	0.0	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.6	1.9	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Buy	Buy	Buy
Consensus Price Target	$21.00	$217.50	$64.00	$23.67	$35.50
% Upside from Price Target	-27.08% downside	20.51% upside	32.23% upside	10.95% upside	49.73% upside
Trade Information
Market Cap	$2.10 billion	$1.85 billion	$4.22 billion	$1.43 billion	$882.23 million
Beta	1.71	1.65	4.56	1.32	2.96
Average Volume	813,101	86,344	30,197,213	557,304	706,857
Sales & Book Value
Annual Revenue	$638.60 million	$122.66 million	$6.84 million	$347.34 million	$3.57 million
Price / Sales	3.39	15.32	595.24	4.12	263.10
Cashflow	$0.71 per share	$1.08 per share	N/A	$2.12 per share	N/A
Price / Cash	40.32	166.71	N/A	10.04	N/A
Book Value	$12.32 per share	$19.72 per share	$1.06 per share	$2.92 per share	$5.83 per share
Price / Book	2.34	9.15	45.66	7.30	4.07
Profitability
Net Income	$-199,500,000.00	$-1,470,000.00	$-20,040,000.00	$31.67 million	$-50,880,000.00
EPS	($0.35)	$0.05	($0.73)	$1.17	($3.28)
Trailing P/E Ratio	N/A	N/A	N/A	266.66	N/A
Forward P/E Ratio	N/A	N/A	2,420.00	43.53	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-32.49%	-11.15%	-250.06%	0.12%	-1,069.42%
Return on Equity (ROE)	-4.07%	-2.29%	-51.38%	11.05%	-30.93%
Return on Assets (ROA)	-2.68%	-1.64%	-47.50%	5.43%	-26.55%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.25%	0.18%	N/A	0.40%	N/A
Current Ratio	2.95%	4.96%	32.21%	2.25%	16.63%
Quick Ratio	2.75%	3.79%	32.21%	1.79%	16.63%
Ownership Information
Institutional Ownership Percentage	96.72%	96.11%	9.01%	84.95%	80.15%
Insider Ownership Percentage	2.80%	11.70%	3.50%	2.08%	2.40%
Miscellaneous
Employees	2,700	602	6	595	123
Shares Outstanding	75.21 million	10.42 million	84.12 million	67.03 million	39.62 million
Next Earnings Date	5/4/2021 (Estimated)	5/6/2021 (Confirmed)	5/10/2021 (Estimated)	4/29/2021 (Estimated)	5/5/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Celldex Therapeutics (NASDAQ:CLDX) Is In A Strong Position To Grow Its Business nasdaq.com - April 13 at 12:00 AM
	Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021 finance.yahoo.com - April 12 at 6:52 PM
	Could Celldex Be a Millionaire-Maker Stock? finance.yahoo.com - April 10 at 9:38 AM
	Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down to $21.00 americanbankingnews.com - April 9 at 11:42 AM
	Celldex Therapeutics (NASDAQ:CLDX) Trading 3.7% Higher americanbankingnews.com - April 7 at 2:38 PM
	Celldex Therapeutics (NASDAQ:CLDX) Shares Down 5% americanbankingnews.com - April 6 at 2:30 PM
	Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Post Earnings of -$0.37 Per Share americanbankingnews.com - April 2 at 2:12 AM
	FY2021 EPS Estimates for Celldex Therapeutics, Inc. Increased by Cantor Fitzgerald (NASDAQ:CLDX) americanbankingnews.com - April 1 at 8:36 AM
	Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 6.7% americanbankingnews.com - March 31 at 12:00 PM
	Celldex Therapeutics Stock Appears To Be Significantly Overvalued finance.yahoo.com - March 31 at 1:56 AM
	Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of ... apnews.com - March 30 at 10:41 AM
	Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down Following Weak Earnings americanbankingnews.com - March 30 at 10:40 AM
	Celldex Therapeutics (NASDAQ:CLDX) Issues Quarterly Earnings Results americanbankingnews.com - March 30 at 7:24 AM
	Celldex: Q4 Earnings Snapshot myplainview.com - March 29 at 8:04 PM
	Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results finance.yahoo.com - March 29 at 8:04 PM
	Why Is It Moving? Looking Into Why Celldex Therapeutics's Stock is Trading Lower Today msn.com - March 29 at 3:04 PM
	Why Celldex Therapeutics Stock Is Tanking Today finance.yahoo.com - March 29 at 3:04 PM
	Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume americanbankingnews.com - March 29 at 12:51 PM
	Celldex's CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy Study markets.businessinsider.com - March 29 at 10:03 AM
	Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria finance.yahoo.com - March 29 at 10:03 AM
	Nasdaq Today – Acadia’s Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week fintechzoom.com - March 28 at 9:19 AM
	Celldex Therapeutics (NASDAQ:CLDX) Shares Down 6.4% americanbankingnews.com - March 26 at 1:50 PM
	Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s Analysis Might Be Just What You’re Looking For stocksregister.com - March 26 at 9:53 AM
	First Week of April 16th Options Trading For Celldex Therapeutics (CLDX) nasdaq.com - March 23 at 3:48 PM
	Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $25.09 americanbankingnews.com - March 22 at 11:30 AM

Date	Company	Brokerage	Action
3/2/2021	Myriad Genetics	SVB Leerink	Boost Price Target
11/10/2020	Myriad Genetics	Piper Sandler	Boost Price Target
8/14/2020	Myriad Genetics	Needham & Company LLC	Reiterated Rating
5/6/2020	Myriad Genetics	JPMorgan Chase & Co.	Lower Price Target
4/2/2020	Myriad Genetics	Bank of America	Lower Price Target
3/26/2020	Myriad Genetics	Barclays	Lower Price Target
11/5/2019	Myriad Genetics	Piper Jaffray Companies	Lower Price Target
8/14/2019	Myriad Genetics	Deutsche Bank Aktiengesellschaft	Lower Price Target
3/3/2021	Heska	Raymond James	Boost Price Target
2/24/2021	Heska	Alliance Global Partners	Reiterated Rating
3/27/2020	Heska	Sidoti	Lower Price Target
11/6/2019	Heska	Canaccord Genuity	Reiterated Rating
5/23/2019	Heska	Guggenheim	Initiated Coverage
2/27/2019	Heska	B. Riley	Lower Price Target
4/1/2021	Riot Blockchain	HC Wainwright	Boost Price Target
3/4/2021	Lantheus	Credit Suisse Group	Boost Price Target
6/29/2020	Lantheus	Jefferies Financial Group	Initiated Coverage
6/16/2020	Lantheus	CJS Securities	Upgrade
8/2/2018	Lantheus	Wells Fargo & Company	Lower Price Target
2/23/2021	Celldex Therapeutics	Cantor Fitzgerald	Boost Price Target
11/17/2020	Celldex Therapeutics	Lifesci Capital	Reiterated Rating
8/9/2018	Celldex Therapeutics	Cowen	Reiterated Rating

(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources